Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest

Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest?
Charles River Laboratories (CRL) reported comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest of -$34.5M in Q1 2026.
How has Charles River Laboratories's comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest changed year-over-year?
Charles River Laboratories's comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest decreased by 144.7% year-over-year, from $77.12M to -$34.5M.
What does comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest mean?
The total change in company equity from all sources, including noncontrolling interests, after taxes.
How do you interpret comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest?
A positive value indicates an overall increase in the company's net worth from non-operating activities, while a negative value indicates a decrease.
How does comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest compare across companies?
Standard reporting metric for consolidated financial statements.